As of November 6, 2026, Lexicon Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: LXRX). The largest holder reporting an active stake on Schedule 13D is Invus Global Management, LLC, at 39.4%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (15%). 3 federal court cases match its legal name and state (Schedule 13D/A, May 8, 2026).
Is this your company?
About to sign with, pay or invest in Lexicon Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lexicon Pharmaceuticals, Inc. a real, registered company?
- Lexicon Pharmaceuticals Inc files with the SEC under CIK 1062822 (its SEC filings).
- Its shares are listed under the ticker LXRX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in The Woodlands, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court record: 3 federal cases name Lexicon Pharmaceuticals, Inc. under its legal name in its state; the latest is Manopla v. Lexicon Pharmaceuticals, Inc., filed 2019-01-28.
- Bankruptcy: no bankruptcy or receivership report found under LEXICON PHARMACEUTICALS, INC. in our SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Lexicon Pharmaceuticals, Inc.'s owners and officers?
Lexicon Pharmaceuticals, Inc.: incorporated in Delaware; business address in The Woodlands, Texas; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2026-02-17)
- : Director (Form D, 2026-02-17)
- : Director (Form D, 2026-02-17)
- : Director (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer, Director (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
- : Executive Officer (Form D, 2026-02-17)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 15% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 11.7% |
| Schedule 13D/A, 2026-05-08 | Invus Global Management, LLC | 39.4% |
| Schedule 13D/A, 2026-02-02 | Invus Global Management, LLC | 36.2% |
| Schedule 13G/A, 2025-07-08 | Fmr LLC | 10.5% |
Questions about who owns Lexicon Pharmaceuticals, Inc.
Who owns Lexicon Pharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Lexicon Pharmaceuticals, Inc.: Invus Global Management, LLC (39.4%, Schedule 13D/A, filed 2026-05-08) and Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05).
Who are the largest shareholders of Lexicon Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Lexicon Pharmaceuticals, Inc. on this page are Invus Global Management, LLC (39.4%) and Fmr LLC (15%).
When did Invus Global Management, LLC buy into Lexicon Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Invus Global Management, LLC on this page is the Schedule 13D/A, filed 2026-02-02, reporting 36.2%; its latest, Schedule 13D/A filed 2026-05-08, reports 39.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lexicon Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lexicon Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexicon Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lexicon Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Westend S.A., a director and 10% owner: 175,156,062 shares (39.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-08).
- Artal International Management S.A., a director and 10% owner: 175,156,062 shares (39.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-08).
- Artal Participations S.a r.l., a director and 10% owner: 175,156,062 shares (39.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-08).
- Artal Group S.A., a director and 10% owner: 175,156,062 shares (39.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-08).
- Artal International S.C.A., a director and 10% owner: 175,156,062 shares (39.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-08).
Shares outstanding: 445,234,571 as of 2026-11-02, from the company's latest SEC cover page.
How much has Lexicon Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-02-17 | $55.67M | $59.15M |
| Form D, 2023-06-20 | $72.22M | $72.22M |
What is Lexicon Pharmaceuticals, Inc.'s court and legal record?
| Case | Court | Filed | Status |
|---|---|---|---|
| Manopla v. Lexicon Pharmaceuticals, Inc. | District Court, S.D. Texas | 2019-01-28 | closed 2020-08-14 |
| Coding Technologies, LLC v. Lexicon Pharmaceuticals, Inc. | District Court, S.D. Texas | 2017-09-14 | closed 2017-12-26 |
| Lexicon Pharmaceuticals, Inc. v. The University of Utah Research Foundation | District Court, S.D. Texas | 2009-01-26 | closed 2009-10-14 |
A docket records that a case was brought, not that anything in it is true.
Keep reading
More on Lexicon Pharmaceuticals, Inc. and the records around it.
Lexicon Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Feb 2026
- Form D filing Feb 2026
Companies that share a holder
- Invus, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Funding and filing history5%+ holdersCourt record
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lexicon-pharmaceuticals-inc